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DNA damage by etoposide activates the 1 isoform of AMP-activated protein kinase in 1 
the nucleus via the Ca
2+
/CaMKK2 pathway, enhancing human tumor cell survival 2 
 3 
1
Diana Vara-Ciruelos*, 
1
Madhumita Dandapani*, 
1
Alexander Gray, 
2
Ejaife O. Agbani, 
2
A. Mark Evans 4 
and 
1
D. Grahame Hardie** 5 
1
Division of Cell Signalling & Immunology, College of Life Sciences, University of Dundee, Dow 6 
Street, Dundee, DD1 5EH, Scotland, UK 7 
2
Centre for Integrative Physiology, University of Edinburgh, Hugh Robson Building, George Square, 8 
Edinburgh EH8 9XD, Scotland, UK 9 
**Corresponding author: Prof. D.G. Hardie, Division of Cell Signalling & Immunology, College of 10 
Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, Scotland, UK; e-mail: 11 
d.g.hardie@dundee.ac.uk; Tel: +44 (1382) 384253 12 
*joint first authors 13 
Running title:  Activation of AMPK by etoposide enhances cell survival 14 
Keywords: AMP-activated protein kinase; CaMKK; DNA damage; etoposide; cell survival 15 
Length of main text: 5,907 words 16 
Number of Figures: 7 17 
Number of Tables: 0 18 
The authors declare no potential conflicts of interest. 19 
DVC was supported by a Programme Grant (C37030/A15101) awarded to DGH by Cancer Research 20 
UK, MD by a Clinical PhD studentship from the Wellcome Trust, and AG by a Senior Investigator 21 
Award (097726) to DGH by the Wellcome Trust. DGH was also indirectly supported by the 22 
pharmaceutical companies supporting the Division of Signal Transduction Therapy at Dundee 23 
(Boehringer-Ingelheim, GlaxoSmithKline and Merck KgaA). OAE and AME were supported by a 24 
Programme Grant (081195) from the Wellcome Trust. 25 
  26 
Vara-Ciruelos et al Activation of AMPK by etoposide enhances cell survival 2 
Abstract 27 
Many genotoxic cancer treatments activate AMPK, but the mechanisms of AMPK activation in 28 
response to DNA damage, and its downstream consequences, have been unclear. We report that 29 
etoposide treatment of cells activates the 1 but not the 2 isoform of AMPK, primarily within the 30 
nucleus. AMPK activation is independent of the DNA damage-activated kinase ATM, and of the 31 
principal upstream kinase for AMPK, LKB1, but correlates with increased nuclear Ca
2+
 and requires 32 
the Ca
2+
/calmodulin-dependent kinase, CaMKK2. Intriguingly, Ca
2+
-dependent activation of AMPK in 33 
two different LKB1-null cancer cell lines caused G1 cell cycle arrest, and enhanced cell 34 
viability/survival after etoposide treatment, with both effects being abolished by knockout of AMPK-35 
1 and -2. The CDK4/CDK6 inhibitor palbociclib also caused G1 arrest in G361 but not HeLa cells 36 
and, consistent with this, enhanced cell survival after etoposide treatment only in G361 cells. These 37 
results suggest that AMPK activation protects cells against etoposide by limiting entry into S phase, 38 
where they would be more vulnerable to genotoxic stress. 39 
Implications 40 
Our results suggest that the 1 isoform of AMPK promotes tumorigenesis by protecting cells against 41 
genotoxic stress, which may explain findings that the gene encoding AMPK-1 (but not -2) is 42 
amplified in some human cancers. They also suggest that 1-selective inhibitors might enhance anti-43 
cancer effects of genotoxic treatments such as etoposide. 44 
Introduction 45 
The wild mandrake or May Apple (Podophyllum peltatum), which was used in traditional native 46 
American medicine, contains the natural product podophyllotoxin (1). Podophyllotoxin itself proved to 47 
be too toxic for human use, but the synthetic derivative etoposide (also known as VP-16) was approved 48 
for cancer treatment in 1983. Etoposide acts by binding to topoisomerase II (2), an enzyme that can 49 
relax DNA supercoiling, insert or remove knots, and catenate or decatenate DNA. It catalyzes an ATP-50 
dependent cycle in which both strands of one DNA helix are broken, followed by passage through this 51 
break of a second helix and religation of the breaks in the first. By inhibiting the religation step, 52 
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etoposide and other anti-cancer agents such as doxorubicin create double-strand breaks. They can also 53 
cause trapping of complexes in which tyrosine residues of the topoisomerase II homodimer remain 54 
covalently attached to phosphate groups of the nucleotide at the 5' end of a DNA break, interfering with 55 
subsequent DNA replication and transcription (3). Since topoisomerase II function is particularly 56 
crucial during S phase when DNA is being replicated, rapidly proliferating cells (including tumor cells) 57 
are more susceptible to cell death induced by etoposide than quiescent cells. 58 
 The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status expressed in 59 
essentially all eukaryotic cells, which occurs universally as heterotrimeric complexes comprising 60 
catalytic  subunits and regulatory  and  subunits (4-6). AMPK is activated by phosphorylation of a 61 
conserved threonine residue within the activation loop of the kinase domain on the  subunit, usually 62 
referred to as Thr172. Thr172 is phosphorylated in vivo by a complex containing the tumor suppressor 63 
kinase LKB1, or by Ca
2+
/calmodulin-dependent protein kinase kinases (CaMKKs), especially 64 
CaMKK2 (4-6). The LKB1 complex appears to be constitutively active, but displacement of ATP by 65 
AMP at two or more sites on the regulatory  subunit of AMPK leads to increased net Thr172 66 
phosphorylation. This occurs because AMP binding triggers conformational changes that promote 67 
Thr172 phosphorylation by LKB1 and inhibit Thr172 dephosphorylation by protein phosphatases, with 68 
these effects being mimicked by ADP (7, 8); binding of AMP (but not ADP) also causes further 69 
allosteric activation (9). Because increases in the cellular ADP:ATP ratio (signifying energy deficit) are 70 
always accompanied by even larger increases in the AMP:ATP ratio, these three effects allow AMPK 71 
to act as an ultrasensitive sensor of cellular energy status. The CaMKK2-AMPK pathway appears to be 72 
activated solely by increases in intracellular Ca
2+
, which can be caused by addition to cells of Ca
2+
 73 
ionophores such as A23187, or by hormones or cytokines that increase intracellular Ca
2+
 (4-6). 74 
 Each AMPK subunit exists as multiple isoforms (1/2, 1/2, 1/2/3) encoded by multiple genes 75 
(PRKAA1/2, PRKAB1/2, PRKAG1/2/3). Intriguingly, while the PRKAA2 gene (encoding 2) is quite 76 
often mutated in human cancers, consistent with the idea that it helps to exert the tumor suppressor role 77 
of LKB1, the PRKAA1 and PRKAB2 genes (encoding 1 and 2) are frequently amplified instead, 78 
suggesting that their amplification may be selected for because they promote tumor formation (5, 10). 79 
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The reason for the distinct behaviors of these AMPK-encoding genes in human cancers has been 80 
unclear. 81 
 Fu et al (11) reported that etoposide activated AMPK, and claimed that the effect was dependent on 82 
the protein kinase ataxia-telangiectasia mutated (ATM), because it appeared to be absent in ATM-83 
deficient cells. ATM is a member of the phosphatidylinositol 3-kinase-like kinase (PIKK) family, with 84 
the genetic disorder ataxia-telangiectasia being caused by loss-of-function mutations in the ATM gene. 85 
ATM is activated in normal cells by double strand breaks in DNA, such as those induced by etoposide. 86 
Once activated, ATM autophosphorylates on Ser1981, and phosphorylates downstream targets such as 87 
the histone variant, H2AX, and Structural Maintenance of Chromosomes Protein-1 (SMC1); these 88 
events can be used as biomarkers both for ATM activation and for DNA damage (12). ATM also 89 
phosphorylates LKB1 at Thr366 (13), and it was reported that activation of AMPK by etoposide in 90 
prostate cancer cells was reduced by shRNA-mediated knockdown of either ATM or LKB1 (14), 91 
suggesting the existence of a kinase cascade from ATM to LKB1 to AMPK. Arguing against this, 92 
however, etoposide still activated AMPK in the LKB1-null HeLa cell line (11), while ionizing radiation 93 
(which causes double stranded DNA breaks and also activates ATM) activates AMPK in another 94 
LKB1-null tumor line, A549 cells (15). 95 
 To address these discrepancies, we investigated the mechanism by which etoposide activates 96 
AMPK. We show that activation of AMPK is restricted to the 1 isoform within the nucleus, and does 97 
not require ATM or LKB1 but is dependent on CaMKK2 and triggered by increases in nuclear Ca
2+
. 98 
We also show that prior activation of either isoform enhances cell survival during etoposide treatment. 99 
These results not only provide a potential explanation for the findings that the gene encoding AMPK-100 
1 (but not –2) is amplified in some human cancers, but also suggest that pharmacological inhibitors 101 
of AMPK might make tumor cells more sensitive to death induced by DNA-damaging treatments, and 102 
might therefore be useful adjuncts to chemotherapy or radiotherapy. If these inhibitors were 1-103 
selective, this might avoid potential systemic side effects caused by inhibition of 2 complexes. 104 
Vara-Ciruelos et al Activation of AMPK by etoposide enhances cell survival 5 
Material and Methods 105 
Materials 106 
A23187, nocodazole, propidium iodide , etoposide, palbociclib, STO609 and KU-5593 were from 107 
Sigma-Aldrich. Antibodies against actin (A5441) were from Sigma-Aldrich, against p-AMPK (pT172; 108 
A2535), p-ATM (pS1981; 4526) and total ATM (2631) were from Cell Signaling, against phospho-109 
SMC1 (S966-P; A300-050A) and total SMC1 (A300-055A) were from Bethyl labs. Antibodies against 110 
AMPK-α1 and -α2, the phosphorylated form of acetyl-CoA carboxylase (pACC) and total ACC have 111 
been described previously (16, 17). Secondary antibodies were from Li-Cor Biosciences. 112 
Cell culture 113 
All cell lines were from the European Collection of Authenticated Cell Cultures (ECACC), except 114 
immortalized mouse embryo fibroblasts (MEFS), which were a gift from Dr Benoit Viollet, INSERM, 115 
Paris (18). HeLa and G361 cells were re-validated during the project by STR profiling (Public Health 116 
England, certificate dated 08/14/2015); HEK-293 cells used in Fig. 2C and Supplementary Fig. S2 117 
were purchased from ECACC in January 2016. G361 cells were cultured in McCoy’s 5A medium 118 
containing 1% (v/v) glutamine, 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) 119 
penicillin/streptomycin. HeLa and HEK-293 cells and MEFs were cultured in Dulbecco’s Modified 120 
Eagle’s Medium (DMEM) with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin. 121 
AMPK assays 122 
Endogenous AMPK isoforms were assayed by immunoprecipitate kinase assays as described (19, 20) 123 
using the AMARA peptide (21) as substrate. AMPK-1 or –2 were assayed by immunoprecipitation 124 
with 1- or 2-specific antibodies, whereas total AMPK was assayed by immunoprecipitation with an 125 
equal mixture of 1- and 2-specific antibodies. 126 
Construction of AMPK knockout cells 127 
Knockout of AMPK-α1 and -α2 (PRKAA1 and PRKAA2) in G361 and HeLa cells was carried out using 128 
the CRISPR-Cas9 method, as described previously for G361 cells (22). 129 
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Immunofluorescence microscopy 130 
Cells were grown on glass coverslips in 6 well dishes until 40-80% confluent and then treated with 131 
drugs or vehicle control. The coverslips were washed 3x in PBS, fixed in 4% paraformaldehyde in PBS 132 
for 20 min, and washed again 3x with PBS. The cells were then permeabilised in 0.2% Triton X-100 in 133 
PBS for 5 min, and washed again 3x with PBS. They were then placed in blocking buffer (PBS with 134 
0.2% fish skin gelatin) for 1 hr and stained with primary antibody (1:300- 1:1000 in blocking buffer) 135 
for 30 min. After further washing in blocking buffer, the coverslips were incubated with fluorescent 136 
secondary antibody (1:200 dilution in blocking buffer) for 30 min. They were then mounted on slides 137 
using Vectashield and sealed with nail varnish. The slides were imaged on the Deltavision 138 
deconvolution microscope and images acquired and deconvolved using the SoftWorx program. 139 
Live cell imaging with Fluo4 140 
Cells were grown on glass bottom dishes (Willco Wells) until 40-80% confluent. They were then 141 
loaded with Fluo4-AM dye (1 μM) plus Hoechst 33342 for 20-30 min. The cells were then washed 142 
with PBS and fresh medium added. The Willco dish was mounted onto a stage pre-heated to 37
o
C and 143 
enclosed with a lid to deliver 5% CO2 to the cells. Calcium flux was measured using the DeltaVision 144 
OMX system with fluorescence measured at 488 nm using a 63x objective. Image analysis and 145 
quantification was performed using ImageJ software. 146 
siRNA knockdown of CaMKK2 147 
Reverse transfection of siRNA constructs against CaMKK2 were carried out according to protocols 148 
detailed in the Ambion™ siRNA starter kit. Briefly, transfection reagent (siPORT) was diluted 1 in 20 149 
in Opti-MEM medium and allowed to incubate for 10 min. Meanwhile, cells were trypsinised for 5 150 
minutes and the trypsin quenched with complete media. siRNA (Ambion, Life Technologies) was 151 
diluted in Opti-MEM to a final concentration of 5 nM. siRNA and diluted transfection reagent were 152 
then mixed and incubated for 10 min. The siRNA- siPORT mixture was added to 6 well plates and 153 
cells were seeded into the 6 well plates. The plates were returned to the incubator for 24 hr, after which 154 
treatment with vehicle or drugs was carried out. Knockdown was confirmed by Western blotting. 155 
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Clonogenic and MTT survival assays 156 
For clonogenic survival assays, cells were seeded into 6 well plates at equal density and treated at 40-157 
80% confluence with vehicle control or different concentrations of drug for 24 hr. Cells were 158 
trypsinized in 0.5 ml of trypsin:EDTA for 5 min and then diluted with 1 ml of complete medium. The 159 
cells in the control flask were counted using a hemocytometer under a microscope and 2000 cells 160 
seeded in triplicate into 10 cm dishes containing 10 ml of medium. The same volume of cell suspension 161 
was aspirated from the treated flasks and seeded in triplicate into 10 cm dishes also containing 10 ml of 162 
medium. The dishes were placed at 37 ºC in an incubator for 10-15 days. On last day, the medium was 163 
aspirated; the cells were fixed with ice-cold methanol for 10 min and stained with 0.3% w/v methylene 164 
blue in methanol for 10 min. The dishes were washed with de-ionised water and the number of colonies 165 
counted manually. 166 
 For MTT assays, cells were seeded in 12 well plates until 40-80% confluence and treated for 48 hr. 167 
The cells were then incubated with 0.5% of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 168 
bromide (MTT) for 3 hr. The growth medium was aspirated off and formazan crystals were dissolved 169 
in 500 µl of acidified isopropanol. The intensity was measured by spectrophotometry at 570 nm. 170 
Cell cycle analysis 171 
Cells were seeded in 6 cm dishes until 40-80% confluence and treated for 16-18 hr. Cells were 172 
trypsinized and the cells were pelleted, transferred into 5 ml Falcon tubes and washed with PBS 173 
containing 1% fetal calf serum and 0.1 mM EDTA. The cells were then fixed with ice-cold 70% 174 
ethanol for >2 hr. The cells were washed twice in the PBS buffer and stained with propidium iodide 175 
(diluted 1 in 20 in the PBS buffer) with RNAse added to digest RNA. Cell cycle analysis was 176 
performed on the Calibur flow cytometer and analysis performed using Flow Jo software. 177 
Additional analytical procedures 178 
SDS-PAGE was performed using precast Bis-Tris 4–12% gradient polyacrylamide gels in the MOPS 179 
buffer system (Invitrogen). Proteins were transferred to nitrocellulose membranes (BioRad) using the 180 
Xcell II Blot Module (Invitrogen). Membranes were blocked for 1 hr in Tris-buffered saline (TBS) 181 
containing 5% (w/v) non-fat dried skimmed milk. The membranes were probed with appropriate 182 
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antibody (0.1–1 μg/ml) in TBS-Tween and 2% (w/v) non-fat dried skimmed milk. Detection was 183 
performed using secondary antibody (1 g/ml) coupled to IR 680 or IR 800 dye, and the membranes 184 
scanned using the Li-Cor Odyssey IR imager.  185 
Presentation of data and statistical analysis 186 
Significances of differences were estimated using GraphPad Prism 6 for Mac OSX, using Student’s t 187 
test, 1-way or 2-way ANOVA as appropriate. Unless stated otherwise, Sidak’s multiple comparison test 188 
was used for post-hoc analysis. Numbers of replicates (n) refer to biological replicates, i.e. the number 189 
of independent cell cultures analyzed. Significance of differences are indicated as follows: *P<0.05, 190 
**P<0.01, ***P<0.001, ****P<0.0001 or †P<0.05, ††P<0.01, †††P<0.001, ††††P<0.0001; ns, not 191 
significant. 192 
Results 193 
AMPK activation by etoposide does not require LKB1 194 
We initially studied the effects of etoposide in cell lines expressing LKB1, including the human 195 
embryonic kidney cell line, HEK-293. Surprisingly, we could not detect significant AMPK activation 196 
in these cells using kinase assays, although it could be readily observed in two LKB1-null tumor cell 197 
lines, i.e. HeLa (cervical cancer) and G361 (melanoma) cells. We could also observe AMPK activation 198 
in immortalized mouse embryo fibroblasts (MEFs), which do express LKB1 (Fig. 1A). 199 
 In HeLa cells, AMPK activation following addition of 30 µM etoposide was quite slow and 200 
relatively modest in extent, becoming significant by 6-9 hours and reaching a maximum of 2- to 3-fold 201 
after 18 hours (see Fig. 5A). Infusion of high-dose etoposide in humans results in peak plasma 202 
concentrations ranging from 50-200 µM (23), and AMPK activation after 16 hr treatment of HeLa cells 203 
occurred at etoposide concentrations from 30 to 300 µM (Fig. 1B). AMPK activation was associated 204 
with increased Thr172 phosphorylation, by 1.8 ± 0.3-fold (n.s.), 2.2 ± 0.3-fold (P <0.05) and 2.3 ± 0.3-205 
fold (P <0.05) at 30, 100 and 300 µM etoposide respectively (mean ± SEM, n = 6), and with 206 
phosphorylation of the ATM substrate SMC1, although phosphorylation of the latter appeared to be 207 
saturated at 30 µM (Fig. 1B). As expected, activation and Thr172 phosphorylation of AMPK was also 208 
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observed following treatment of HeLa cells with the Ca
2+
 ionophore A23187 (which activates the 209 
upstream kinase CaMKK2) although the degree of activation was larger than that obtained with 210 
etoposide. However, A23187 treatment did not lead to phosphorylation of SMC1, suggesting that ATM 211 
was not activated by increasing cellular Ca
2+
 (Fig. 1B). Very similar effects of etoposide and A23187 212 
were observed in G361 cells (Fig. 1C), where the effects of etoposide on Thr172 phosphorylation were 213 
2.1 ± 0.1-fold (n.s.), 3.5 ± 0.4-fold (P <0.001) and 3.7 ± 0.5-fold (P <0.001) at 30, 100 and 300 µM 214 
respectively (mean ± SEM, n = 4). 215 
AMPK activation by etoposide occurs primarily within the nucleus 216 
Fig. 2A shows fluorescence micrographs of HeLa cells treated with vehicle (DMSO), etoposide (100 217 
µM) or A23187. The cells were fixed and labeled with antibodies recognizing ATM phosphorylated at 218 
Ser1981 (pATM) or AMPK phosphorylated at Thr172 (pT172). Quantification of the nuclear and 219 
cytoplasmic fluorescence is shown in Fig. 2B, left-hand panels (n = 10). As expected, large increases 220 
(13-fold) in nuclear staining were obtained with the anti-pATM antibody after treatment with 221 
etoposide, but not A23187. By contrast, large increases in nuclear staining were obtained with anti-222 
pT172 antibody after treatment with either etoposide (13-fold) or A23187 (9-fold). Although A23187 223 
also appeared to increase cytoplasmic pT172 staining in HeLa cells, this was not statistically 224 
significant. Similar results were obtained with G361 cells, although in these cells A23187 did cause a 225 
significant increase in cytoplasmic pT172 staining (Supplementary Fig. S1; quantification in Fig, 2C, 226 
right). These results show that etoposide activates AMPK primarily in the nucleus, in both HeLa and 227 
G361 cells. 228 
 Using the anti-pT172 antibody to detect AMPK activation in HeLa cells, fluorescence could be 229 
observed in most nuclei after treatment for 18 hr with 100 µM etoposide, but was still observed in some 230 
nuclei even at much lower etoposide concentrations (250 nM, Supplementary Fig. S2, arrows); these 231 
invariably corresponded with nuclei that were also positive for pATM, indicating the occurrence of 232 
DNA damage. 233 
 Because basal Thr172 phosphorylation and AMPK activity is much higher in the cytoplasm of cells 234 
that express LKB1 such as HEK-293 cells (24), we hypothesized that this might have been masking 235 
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changes in the small pool of AMPK in the nucleus, explaining why we had not been able to initially 236 
detect effects of etoposide in HEK-293 cells. Consistent with this, in control HEK-293 cells treated 237 
with DMSO for 18 hr there was a diffuse cytoplasmic and nuclear fluorescence detected using anti-238 
pT172 antibodies, such that it was difficult to distinguish the two compartments. Most cells also 239 
displayed at least one perinuclear patch with more intense fluorescence; these appear to represent the 240 
Golgi apparatus, since they stained with antibodies against the Golgi maker, GM130 (data not shown). 241 
In cells treated with low etoposide concentrations (3 µM) the nuclei were more fluorescent than the 242 
cytoplasm in some cells, once again corresponding with cells where the signal for nuclear pATM was 243 
increased (Supplementary Fig. S3, arrows). Fig. 2C shows quantification of results from a large number 244 
of cells (n = 18). The mean absolute fluorescence appeared to increase in response to etoposide in the 245 
nucleus and decrease in the cytoplasm, while remaining constant when averaged across the whole cell, 246 
although these effects were not statistically significant (left-hand panel). However, when the results 247 
were expressed as nuclear:cytoplasmic ratios there was a significant increase in response to 3 µM 248 
etoposide (right-hand panel). Thus, etoposide appears to activate AMPK within the nuclei of HEK-293 249 
cells, although this is difficult to detect because it can be masked by the high basal activity in the larger 250 
pool of AMPK in the cytoplasm. 251 
AMPK activation by etoposide is specific for the 1 isoform 252 
Because the sequences around Thr172 are identical in 1 and 2, the anti-pT172 antibody does not 253 
distinguish the two AMPK catalytic subunit isoforms. However, human 1 (predicted mass 64,009 Da) 254 
is slightly larger than 2 (62,319 Da), and the two isoforms can be resolved by SDS-PAGE. In Fig. 3A 255 
we analyzed lysates from triplicate dishes of control and etoposide-treated HeLa cells by dual label 256 
Western blotting using anti-pT172 antibodies labeled with IRDye 680 (red), and either 1- or 2-257 
specific antibodies labeled with IRDye800 (green). In the upper blot (probed with anti-pT172 and anti-258 
1) a single band appears predominantly green in the control lanes but becomes more yellow 259 
(indicating increased Thr172 phosphorylation) after etoposide treatment. In the lower blot  (probed 260 
with anti-pT172 and anti-2) two bands are evident, an upper red band (1) that becomes more intense 261 
after etoposide treatment, and a lower green band (2) whose intensity or color does not change. The 262 
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intensity in the pT172 (red) channel for 1 increased by 2.1 ± 0.1-fold (P <0.0001, n = 3) and 2.0 ± 263 
0.1-fold (P = 0.0001, n = 3) in the upper and lower panels respectively, but was unchanged for 2. 264 
These results show that Thr172 phosphorylation in response to etoposide occurs exclusively with the 265 
1 isoform. To confirm this, we immunoprecipitated complexes from cell lysates of HeLa, G361 and 266 
A549 cells using 1- or 2-specific antibodies, and measured kinase activity. The results (Fig. 3B-D) 267 
showed that 30-300 µM etoposide caused progressive activation of 1 complexes in all three cell types. 268 
In HeLa and A549 cells etoposide failed to activate 2 complexes (Figs. 3B, 3D), while in G361 cells 269 
the activity of 2 complexes was too low to measure reliably (Fig. 3C). As a positive control, the Ca2+ 270 
ionophore A23187 markedly activated both 1 and 2 complexes in HeLa and A549 cells, and 1 271 
complexes in G361 cells. We also performed Western blots in A549 cells (Fig. 3E), which showed, 272 
similar to the results in HeLa and G361 cells (Figs. 1B/1C), that pSMC1 phosphorylation was 273 
increased by etoposide but not A231787, whereas there were small increases in Thr172 274 
phosphorylation in response to etoposide and a larger increase in response to A23187, correlating with 275 
the changes in AMPK activity. Interestingly, phosphorylation of the downstream target of AMPK, 276 
acetyl-CoA carboxylase (ACC), did not appear to increase in response to etoposide, although it clearly 277 
increased in response to A23187 (Fig. 3E). 278 
AMPK activation by etoposide requires CaMKK2 but not ATM 279 
Since AMPK activation by etoposide in HeLa, G361 and A549 cells occurs in the absence of LKB1, 280 
we examined whether it required the other well-established upstream kinase for AMPK, CaMKK2. Fig. 281 
4A shows that the CaMKK2 inhibitor STO609 had no effect on etoposide-induced phosphorylation of 282 
SMC1 (which is catalyzed by ATM), but did inhibit basal AMPK activity and Thr172 phosphorylation, 283 
as well as the increases induced by etoposide (although at the concentration used it did not block the 284 
effects of etoposide completely). Fig. 4A shows that (as in A549 cells, Fig. 3E), etoposide did not 285 
increase phosphorylation of the classical AMPK target acetyl-CoA carboxylase (ACC), although in 286 
other experiments  (Fig. 4C) it was phosphorylated in response to A23187. Since STO-609 is not 287 
completely selective for CaMKK2 (17), we also assessed the requirement for CaMKK2 via siRNA 288 
knockdown. Western blots show that we obtained effective CaMKK2 knockdown that blocked AMPK 289 
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activation and Thr172 phosphorylation in response to both etoposide (Fig. 4B) and A23187 (Fig. 4C). 290 
As expected, CaMKK2 knockdown did not affect etoposide-induced phosphorylation of the ATM 291 
target SMC1 (Fig. 4B), although it prevented phosphorylation of ACC in response to A23187 (Fig. 292 
4C). 293 
 To examine the involvement of ATM, we used the ATM-selective inhibitor KU-55933 (25). As 294 
expected, KU-55933 blocked the phosphorylation of the ATM target SMC1 in response to etoposide. 295 
However, although it appeared to cause a modest reduction in basal activity and Thr172 296 
phosphorylation of AMPK, it did not prevent the increased AMPK activity and Thr172 297 
phosphorylation caused by etoposide (Fig. 4D). Thus, in these cells the regulation of AMPK by 298 
etoposide is ATM-independent. 299 
AMPK activation is associated with increases in nuclear [Ca2+] 300 
Since activation and Thr172 phosphorylation of AMPK in response to etoposide required CaMKK2, 301 
we suspected that it might be associated with increases in nuclear Ca
2+
 concentration. Fig. 5A shows a 302 
time course of AMPK activation after addition of etoposide in HeLa cells. After a lag of around 3 303 
hours, AMPK activation became evident by 6 hours and increased further up to 18 hours. We used the 304 
Ca
2+
-sensitive dye fluo-4, administered to cells in the form of the acetoxymethyl ester fluo-4 AM, to 305 
estimate changes in Ca
2+
 within the nucleus and cytoplasm at 3 hr intervals. The ratio of fluorescence at 306 
the time of measurement and at time zero (F/F0), was used as an index of [Ca
2+
]. Interestingly, slow, 307 
progressive increases in nuclear [Ca
2+
] were observed which followed a similar time course to changes 308 
in AMPK activity, becoming significant at 6 hours and continuing to increase up to about 18 hours. 309 
Cytoplasmic Ca
2+
 did not exhibit such significant changes over the same time points (Fig. 5B). 310 
A23187 enhances cell survival during etoposide treatment via AMPK activation 311 
Using the CRISPR-Cas9 system, we generated HeLa and G361 cells with single (1KO or 2KO) or 312 
double (DKO) knockouts of the AMPK catalytic subunits. Fig. 6A shows that 1 and/or2 were 313 
absent from the knockout HeLa cells as expected. Interestingly, 2 expression was markedly up-314 
regulated in 1KO HeLa cells. We were unable to detect 2 by Western blotting in the G361 cells 315 
(Fig. 6B), consistent with our failure to detect it using kinase assays (see above). Also consistent with 316 
Vara-Ciruelos et al Activation of AMPK by etoposide enhances cell survival 13 
this, phosphorylation of the AMPK target ACC in response to the AMPK activator H2O2 (26) was 317 
abolished in G361 cells by knockout of 1 only, although in HeLa cells this required knockout of both 318 
1 and 2 (Fig. 6A/B). 319 
 We next used two types of cell survival assay to assess the effect of prior AMPK activation by 320 
A23187 on cell death induced by etoposide treatment of HeLa cells. Using MTT assays and treatment 321 
for 48 hours (Fig. 6C), 10 or 30 µM etoposide reduced cell survival to 21% and 7% of the DMSO 322 
control, respectively. However, prior treatment with A23187 for 6 hours to activate AMPK 323 
significantly enhanced cell survival to 47% and 14% of control, respectively. Similar protective effects 324 
of A23187 were seen in 1KO and 2KO cells although the basal levels of survival appeared to be 325 
slightly higher in these cells. However, the protective effect of A23187 treatment was completely 326 
abolished in DKO cells at both etoposide concentrations. Similar results were obtained using the more 327 
sensitive clonogenic survival assays (Fig. 6D), although much lower concentrations of etoposide (100 328 
and 250 nM) and shorter incubation times (18 hours) were used in these assays. One other difference 329 
was that clonogenic survival was significantly lower in DKO cells at both 100 and 250 nM etoposide 330 
even in cells not treated with A23187, an effect not seen using the MTT assays. Fig. 6E confirms using 331 
anti-pSMC1 blots that ATM was activated to a similar extent at all four concentrations of etoposide 332 
used in Figs. 6C and 6D, and that this was unaffected by single or double knockouts of the two AMPK 333 
catalytic subunit isoforms. 334 
 We suspected that the protection against cell death provided by AMPK activation might be due to 335 
G1 cell cycle arrest, which would reduce entry of cells into S phase where they would be more 336 
vulnerable to DNA damage induced by etoposide. To confirm that A23187 induced G1 arrest in HeLa 337 
cells, we treated them with or without A23187 in the presence of nocodazole (which prevents cells that 338 
have already traversed the G1:S boundary from progressing through into the subsequent G1 phase). 339 
Fig. 6F shows that A23187 caused a >10-fold increase in G1:G2 ratio in WT cells, as expected for an 340 
agent causing G1 arrest. Similar results were obtained in 1KO or 2KO cells, showing that either 341 
isoform is capable of causing cell cycle arrest. However, a significant increase in G1:G2 ratio was not 342 
observed in DKO cells. 343 
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Other treatments causing G1 arrest provided similar protection against etoposide 344 
To test whether other treatments that caused G1 arrest would provide protection against etoposide-345 
induced cell death, we initially used palbociclib (PBC, also known as PD332991), an inhibitor of the 346 
cyclin-dependent kinases CDK4/CDK6 (27, 28). Interestingly, PBC did not cause cell cycle arrest in 347 
HeLa cells (Fig. 7A). However, in G361 cells PBC from 0.1 to 10 nM caused a progressive increase in 348 
the proportion of G361 cells in G1 phase, with corresponding decreases in the proportions in S and 349 
G2/M phases (Fig. 7B). Tellingly, PBC did not protect against cell death induced by etoposide in 350 
clonogenic survival assays in HeLa cells (Fig. 7C), but provided marked protection in G361 cells (Fig. 351 
7D). We have shown previously that A23187 treatment of G361 cells causes a G1 arrest that is 352 
abolished in AMPK DKO cells (22). Supplementary Fig. S4 confirms that, similar to HeLa cells, prior 353 
treatment with A23187 protected G361 cells against cell death induced by etoposide in clonogenic 354 
survival assays, with the effect being abolished in DKO cells. 355 
 To confirm that another agent that caused cell cycle arrest would protect HeLa cells against 356 
etoposide, we used aphidicolin, which causes arrest in early S phase by inhibiting DNA polymerase- 357 
(29). Unlike palbociclib, aphidicolin cause a marked arrest at the G1/S boundary (Fig. 7E) and also 358 
provided significant protection against cell death induced by etoposide in clonogenic survival assays 359 
(Fig. 7F). 360 
Discussion 361 
We have confirmed that the DNA-damaging agent etoposide activates AMPK in several different cell 362 
lines as reported previously (11, 14), but also present new findings that AMPK activation by etoposide 363 
occurs primarily in the nucleus, and is specific for complexes containing the 1 isoform of the catalytic 364 
subunit even when 2 was also expressed, as in HeLa and A549 cells. Since these cells do not express 365 
LKB1, our results rule out a role for that kinase. We show instead that the effect is catalyzed by the 366 
alternate upstream kinase CaMKK2, since it was reduced either by the CaMKK inhibitor STO-609, or 367 
by knocking down CaMKK2 using siRNA. The correlation between AMPK activation and nuclear 368 
[Ca
2+
] (Fig. 5) suggests that activation of AMPK by etoposide may be mediated by increases in nuclear 369 
[Ca
2+
] rather than any intrinsic change in CaMKK2 activity, although the source of the increased 370 
Vara-Ciruelos et al Activation of AMPK by etoposide enhances cell survival 15 
nuclear Ca
2+
, and the mechanism by which it is released in response to etoposide and/or DNA damage, 371 
remains unclear. 372 
 We were initially unable to detect significant Thr172 phosphorylation or activation of AMPK by 373 
etoposide in HEK-293 cells, which express normal levels of LKB1.  However, we subsequently 374 
observed increased Thr172 phosphorylation in the nuclei of HEK-293 cells by immunofluorescence 375 
microscopy. We believe that we could not detect changes in global Thr172 phosphorylation or AMPK 376 
activation in these cells because the high basal levels of these parameters in the cytoplasm (due to the 377 
high basal activity of LKB1) were obscuring changes in the small pool of AMPK within the nucleus. 378 
 It was previously reported that AMPK activation by etoposide in a prostate cancer cell line (C4-2) 379 
was reduced by knocking down ATM or LKB1 using RNAi (14). Since ATM had been previously 380 
shown to phosphorylate LKB1 at Thr366 (13), it was proposed (14) that there was a kinase cascade 381 
from ATM to LKB1 to AMPK. However, Thr366 phosphorylation has been reported to have no effect 382 
on either the activity or the localization of LKB1 in G361 cells (13). Moreover, this mechanism cannot 383 
explain the effects in the cells we studied because: (i) in HeLa cells, etoposide activated AMPK via a 384 
mechanism that required CaMKK2, but not LKB1; (ii) although etoposide activated ATM in HeLa 385 
cells, the ATM inhibitor KU-55933 did not prevent increased AMPK activity and Thr172 386 
phosphorylation in response to etoposide, despite blocking phosphorylation of a known ATM target, 387 
SMC1.  388 
 One interesting question raised by our study is why AMPK activation by etoposide is restricted to 389 
nuclear 1 complexes. LKB1 is only catalytically active when it forms a complex with the accessory 390 
subunits STRAD and MO25 (30), and association with these subunits causes its exclusion from the 391 
nucleus (31), implying that LKB1 may only be able to activate cytoplasmic AMPK. Consistent with 392 
this, using a FRET-based reporter that can monitor AMPK activity in real time in single cells (32), 393 
AMPK activation by 2-deoxyglucose [an inhibitor of glycolysis that activates AMPK by increasing 394 
cellular AMP, and is therefore LKB1-dependent (33)] occurred only in the cytoplasm, whereas 395 
activation by A23187 [a Ca
2+
 ionophore that works via the Ca
2+
/CaMKK2 pathway independently of 396 
AMP (33)] occurred initially in the cytoplasm and then in the nucleus. These results suggest that 397 
CaMKK2 must be present in the nucleus, since if the effect was due to translocation of activated 398 
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AMPK, it should work equally well after treatment with 2-deoxyglucose or A23187. There is also 399 
evidence that 2-containing complexes are activated primarily by the AMP- and LKB1-dependent 400 
mechanism rather than the Ca
2+
/CaMKK2 mechanism in vivo. For example, conditional LKB1 401 
knockout in skeletal and cardiac muscle prevented activation of 2-containing complexes in response 402 
to contraction in skeletal muscle or ischemia in cardiac muscle, while having little or no effect on the 403 
activity of 1-containing complexes (34, 35). The reasons for this apparent selectivity of upstream 404 
kinases for 1 or 2-containing complexes in vivo remain unclear, because the LKB1:STRAD:MO25 405 
complex  (24) and CaMKK2 (36) phosphorylate and activate both 1- or 2-containing complexes in 406 
cell-free assays, while treatment with the Ca
2+
 ionophore A23187 can activate 2 complexes in intact 407 
cells (Fig. 2B). One possibility is that this isoform selectivity is due to different subcellular locations of 408 
the upstream kinases and the AMPK complexes containing the different  isoforms. Both 1 and 2 409 
contain well-defined nuclear export sequences (37), while nuclear localization sequences are less well-410 
defined, although a short conserved basic sequence in 2 (also present in 1) has been proposed to 411 
fulfill that role (38). If 1 complexes were more abundant than 2 complexes in the nuclei of 412 
unstimulated HeLa or G361 cells, this might explain why only the former were activated by etoposide. 413 
Arguing against this possibility, however, is evidence that it is 2 rather than 1 that is enriched in the 414 
nucleus (39), although that was obtained using different cell types. Interestingly, etoposide treatment 415 
did not cause phosphorylation of ACC at the AMPK site Ser79, unlike A23187 (Figs. 3E, 4A, 4C). 416 
ACC phosphorylation is a universally used biomarker for AMPK activation, and etoposide is the first 417 
AMPK activator we have studied that does not trigger it. The obvious explanation is that etoposide 418 
activates AMPK primarily in the nucleus, from which ACC (a large cytoplasmic protein) is excluded. 419 
 Another novel finding in our study was that prior elevation of intracellular Ca
2+
 for 6 hours using the 420 
Ca
2+
 ionophore A23187 protected against cell death induced by etoposide, both in short-term MTT 421 
assays and in clonogenic survival assays. In both cases, the effect was AMPK-dependent, because it 422 
was eliminated in HeLa and G361 cells when both catalytic subunit isoforms (1 and 2) were 423 
knocked out using the CRISPR-Cas9 system. Single knockouts did not abolish the effect in HeLa cells, 424 
suggesting that either isoform is capable of exerting the protective effect, although we have found that 425 
only 1 complexes are activated by etoposide. A caveat here, however, is that knockout of AMPK-1 426 
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caused a marked up-regulation of AMPK-2 expression (Fig. 6A), raising the possibility that over-427 
expressed AMPK-2 might perform functions that endogenous levels might not. A notable difference 428 
between the MTT and the clonogenic survival assays is that effects of etoposide on cell survival were 429 
observed in clonogenic assays at much lower concentrations (100-250 nM, as opposed to 10-30 µM for 430 
MTT assays). This is a common finding, and may occur because a low level of DNA damage, which 431 
may be quite difficult to detect, is nevertheless sufficient to prevent clonal growth of single cells. 432 
 These findings to some extent turn the original view on the role of AMPK in cancer on its head. 433 
Because AMPK is immediately downstream of, and activated by, the tumor suppressor LKB1, because 434 
it inhibits cell growth and proliferation and switches off the growth-promoting target-of-rapamycin 435 
complex-1 (TORC1) when activated (5, 40), and because use of the AMPK-activating drug metformin 436 
is associated with a lower risk of cancer in diabetics (41), it had been widely assumed that AMPK was 437 
a tumor suppressor. Although AMPK may indeed initially suppress the development of rapidly 438 
growing tumors and there may therefore be selection pressure for the LKB1-AMPK pathway to be 439 
down-regulated (42), complete loss-of-function of AMPK in human cancers appears to be rare. In fact, 440 
there is increasing evidence that AMPK can under some circumstances enhance the growth of tumor 441 
cells, perhaps by protecting solid tumors against the environmental and nutritional stresses that occur 442 
before their new blood supply has been fully established (5, 10, 43, 44). For example, a double 443 
knockout of 1 and 2 isoforms in immortalized MEFs prevented their growth as xenografts in 444 
immunodeficient mice (18). However, while knocking out 2 alone accelerated growth of H-RasV12-445 
transformed MEFs in vivo, knocking out 1 completely prevented growth, suggesting that 1 but not 446 
2 is required for tumor growth in vivo (45). These results are also consistent with results of recent 447 
data mining from the human cancer genome projects, which revealed that while the PRKAA1 gene 448 
(encoding 1) is frequently amplified in human cancers (suggesting that this is a genetic change for 449 
which positive selection has occurred), the PRKAA2 gene (encoding 2) undergoes quite frequent 450 
mutations instead, more consistent with it being a tumor suppressor (5, 10). The results shown in Fig. 6 451 
provide the novel finding that AMPK activation using A23187 in LKB1-null tumor cells protects them 452 
against cell death induced by the DNA damaging agent, etoposide, and that this is abolished in the 453 
absence of AMPK. Since etoposide treatment activates AMPK on its own, the presence of AMPK 454 
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should be sufficient to protect the cells against etoposide, even in the absence of A23187. This was 455 
indeed the case in clonogenic survival assays in HeLa cells, where cell death was enhanced in the DKO 456 
cells not treated with A23187 (Fig. 6D). These results suggest that an AMPK inhibitor (particularly if 457 
selective for 1 complexes) might be a useful adjunct to treatment with etoposide, and perhaps other 458 
cancer therapies that damage DNA, such as doxorubicin or radiotherapy. 459 
 What is the mechanism by which AMPK protects tumor cells against the effects of DNA-damaging 460 
agents such as etoposide? AMPK activation using the pharmacological activator 5-aminoimidazole-4-461 
carboxamide ribonucleoside (46), or by glucose deprivation or over-expression of a mutant (T172D) 462 
AMPK kinase domain (47), causes cell cycle arrest in G1 phase. We have recently confirmed that these 463 
effects of AMPK activators, which are associated with increased expression of the cyclin-dependent 464 
kinase inhibitor p21 (CDKN1A), are AMPK-dependent since they were abolished by a double 465 
knockout of AMPK (22). A cell cycle arrest in G1 phase would limit the entry of cells into S phase, 466 
where they are particularly vulnerable to the generation of double-stranded DNA breaks induced by 467 
etoposide while DNA is being replicated. Supporting this proposal, palbociclib, a potent and selective 468 
inhibitor of the G1 cyclin-dependent kinases CDK4/CDK6 (27, 28), caused G1 arrest in G361 cells 469 
while not arresting HeLa cells and, correlating with this, prior treatment of G361 but not HeLa cells 470 
with palbociclib provided marked protection against cell death induced by etoposide. By contrast, 471 
aphidicolin caused a G1:S phase cycle arrest in HeLa cells and also protected them against cell death 472 
induced by etoposide. Sensitivity of different tumor cell lines to palbociclib has been shown to be 473 
inversely correlated with the expression of the CDK inhibitor p16 (CDKN2A) (48, 49). This may 474 
explain why the effect of the inhibitor differs between these two cell lines, since p16 is expressed at 475 
much higher levels in HeLa than in G361 cells (50). 476 
 In summary, DNA-damaging treatments such as etoposide (11) and ionizing radiation (15) have 477 
been previously reported to activate AMPK, and it was suggested that the effect of etoposide occurred 478 
via a kinase cascade from ATM to LKB1 to AMPK (14). However, we show that the effect of 479 
etoposide is independent of ATM and LKB1, and involves instead an increase in nuclear Ca
2+
 that 480 
causes activation of CaMKK2. AMPK activation is restricted to the 1 isoform and occurs within the 481 
nucleus, so that phosphorylation of ACC, the classical marker for AMPK activation, is not observed. 482 
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Moreover, prior AMPK activation using A23187 in two different LKB1-null tumor cell lines protects 483 
against cell death induced by etoposide, and this was AMPK-dependent because the effect was 484 
abolished when both isoforms of AMPK were knocked out. Taken together with findings that AMPK-485 
1 is required for growth of transformed mouse embryo fibroblasts as tumors in vivo (45), and that the 486 
gene encoding AMPK-1 is frequently amplified in human tumors (5, 10), this suggests that AMPK 487 
inhibitors, and particularly selective inhibitors of AMPK-1, might be useful adjuncts to cytotoxic 488 
drugs, and perhaps also radiotherapy, in human cancer. 489 
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FIGURE LEGENDS 611 
Figure 1: Activation of AMPK by etoposide in different cell types. (A) HeLa cells, G361 cells and 612 
immortalized mouse embryo fibroblasts (MEFs) were incubated with 30 µM etoposide for 613 
18 hr (HeLa, G361) or with 20 µM etoposide for 2 hr (MEFs). Cell lysates were 614 
immunoprecipitated with anti-AMPK-1 and –2 antibodies for AMPK assay. Results are 615 
expressed relative to the mean activity (± SEM) in incubations without etoposide; results 616 
significantly different from the DMSO control by t test are indicated (HeLa and G361 cells, 617 
n = 4; MEFs, n = 3). (B) HeLa cells were incubated with increasing concentrations of 618 
etoposide, or with 10 µM A23187, for 18 hr. Upper panel: lysates were immunoprecipitated 619 
with a mixture of anti-AMPK-1 and –2 antibodies for AMPK assay. Results are 620 
expressed relative to the mean activity (± SEM) in incubations without etoposide or 621 
A23187 (n = 3). Results significantly different from the DMSO control by 1 way ANOVA 622 
are indicated. Equal amounts of protein from lysates from two of the three experiments 623 
were analyzed by Western blotting using anti-pSMC1, total SMC1, anti-pT172 (phospho-624 
AMPK) and a mixture of anti-1 and –2 antibodies. (C) As (B), but using G361 cells. 625 
Vara-Ciruelos et al Activation of AMPK by etoposide enhances cell survival 25 
Figure 2: Etoposide activates AMPK in the nucleus. (A) Fluorescence micrographs of HeLa cells 626 
treated for 18 hr with DMSO (control), 100 µM etoposide or 10 µM A23187. Cells were 627 
fixed, permeabilized, and stained with 4',6-diamidino-2-phenylindole (DAPI, blue), anti-628 
pATM labelled with FITC (green) and anti-pT172 labelled with Texas red. In the right-629 
hand images the green and red channels have been merged to assess the co-localization of 630 
pATM and pT172. Arrows show nuclei prominently labelled with anti-pT172 antibody. (B) 631 
Quantification of nuclear and cytoplasmic staining with anti-pATM and anti-pT172 in 632 
HeLa cells (left) and G361 cells (right). Using ImageJ software, the total cell area was 633 
defined, as was the area of the nuclei defined by DAPI staining. The mean fluorescence 634 
intensity in the nucleus and the cytoplasm of the etoposide- or A23187-treated cells are 635 
expressed relative to that of DMSO controls. Results are mean ± SEM (n = 10) and 636 
statistical significance of differences from DMSO controls are indicated (ns, not 637 
significant). (C) Quantification of effects of etoposide on nuclear and cytoplasmic 638 
localization of pAMPK in HEK-293 cells; analysis as in (B). Results are mean ± SEM (n = 639 
18); ns, not significant. 640 
Figure 3: Activation of AMPK by etoposide is specific for the 1 isoform. (A) HeLa cells were 641 
treated in triplicate with DMSO (control) or with 30 µM etoposide for 18 hr. Lysates were 642 
prepared and equal protein loadings analyzed by SDS-PAGE and Western blotting using 643 
anti-pT172 labelled with IRDye 680 (red), together with either anti-AMPK-1 (top panel) 644 
or anti-AMPK-2 (bottom panel) labeled with IRDye 800 (green). (B) HeLa cells were 645 
treated as in Fig. 1B, except that 1- or 2-containing complexes were immunoprecipitated 646 
separately before AMPK assay. (C), as (B), but using G361 cells; the activity of 2-647 
containing complexes was too low to measure reliably. (D), as (B), but using A549 cells. In 648 
(B) - (D), results are mean ± SEM (n = 4 in B, n = 6-9 in C, n = 7-10 in D); statistical 649 
significnce of differences from DMSO controls are indicated. 650 
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Figure 4: Etoposide effects on AMPK require CaMKK2 but not ATM. (A) HeLa cells were 651 
treated with 30 µM etoposide for 18 hr with or without pre-treatment for 1 hr with 25 µM 652 
STO-609. Total AMPK was immunoprecipitated and assayed (top panel; mean ± SEM, n = 653 
3) and Western blots of duplicate dishes of cells analyzed using various antibodies (bottom 654 
panel). (B) HeLa cells were treated with scrambled siRNA or siRNA targeted at CaMKK2 655 
for 24 hr, prior to treatment with or without 30 µM etoposide for 18 hr; other analyses as in 656 
(A). (C) HeLa cells were treated with scrambled siRNA or siRNA targeted at CaMKK2 for 657 
24 hr, prior to treatment with or without 10 µM A23187 for 1 hr; other analyses as in (A). 658 
(D) HeLa cells were treated with 30 µM etoposide for 18 hr with or without pre-treatment 659 
for 1 hr with 10 µM KU-55933. Total AMPK was immunoprecipitated and assayed (top 660 
panel; mean ± SEM, n = 3) and Western blots of duplicate dishes of cells analyzed using 661 
various antibodies (bottom panel). 662 
Figure 5: The effect of etoposide on AMPK correlates with an increase in nuclear Ca
2+
. (A) 663 
Time course of AMPK activation in HeLa cells during treatment with 30 µM etoposide; 664 
results are mean ± SEM (n = 3); values significantly different from zero time value are 665 
indicated. (B) Time course of changes in nuclear and cytoplasmic Ca
2+
 in HeLa cells during 666 
treatment with 30 µM etoposide. Results (F/Fo, i.e. fluorescence as a ratio of mean 667 
fluorescence at time zero) are expressed as mean ± 95% confidence intervals (n = 12) with 668 
significant differences between etoposide-treated and control indicated at each time point. 669 
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Figure 6: HeLa and G361 cells are protected against etoposide-induced cell death by prior 670 
AMPK activation using A23187. (A) Parental HeLa cells (WT) or HeLa cells with 671 
CRISPR-Cas9 knockouts of AMPK-1 (1KO), AMPK-2 (2KO) or both (DKO) were 672 
treated in duplicate with 1 mM H2O2 for 10 min. Cell lysates were then analysed by 673 
Western blotting using the indicated antibodies. (B) As (A), but using G361 cells. (C) 674 
Survival of WT, single or double knockout HeLa cells assessed using MTT assays, 675 
following treatment with 10 or 30 µM etoposide for 18 hr, with or without prior treatment 676 
with 10 µM A23187 for 6 hr. Results are mean ± SEM (n = 12). Where appropriate, 677 
statistical significance is indicated by asterisks for differences between treatments with and 678 
without A23817; ns = not significant. (D) Survival of WT, single or double knockout HeLa 679 
cells assessed using clonogenic assays, following treatment with 100 or 250 nM etoposide 680 
for 18 hr, with or without prior treatment with 10 µM A23187 for 6 hr. Results are numbers 681 
of colonies counted (mean ± SEM; n = 4) expressed as a percentage of colony numbers in 682 
controls without etoposide. Where appropriate, statistical significance is indicated by 683 
asterisks for differences between treatments with and without A23817, and by daggers (†) 684 
for differences between WT and  DKO; ns = not significant. (E) Phosphorylation of SMC1 685 
in HeLa cells treated with or without different concentrations of etoposide as in (C) and 686 
(D); (F) Cell cycle arrest in WT, single or double knockout HeLa cells treated with or 687 
without 3 µM A23187 for 6 hr and then 70 ng/ml nocodazole for a further 18 hr. The cells 688 
were then fixed, stained and analyzed by flow cytometry to determine DNA content and 689 
hence cell cycle phase. Results are expressed as ratios of cells in G1:G2 phase (mean ± 690 
SEM; n = 4). Asterisks indicate the significance of differences between cells treated with 691 
and without A23187; ns, not significant. 692 
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Figure 7: Protection against cell death using the CDK4/6 inhibitor palbociclib (PBC) correlates 693 
with its ability to cause a G1 cell cycle arrest. (A) HeLa cells were treated with the 694 
indicated concentrations of PBC for 6 hr and then with nocodazole (70 ng/ml) for 18 hr, 695 
after which cells were fixed, stained with propidium iodide and subject to cell cycle 696 
analysis by flow cytometry. Results (mean ± SEM; n = 4) show the proportion of cells in 697 
each cell cycle phase; none of the differences between PBC treatment and controls were 698 
significant. (B) as (A), but using G361 cells; asterisks show statistically significant 699 
differences from controls without PBC. (C) Clonogenic survival of HeLa cells after 700 
treatment with or without PBC (3 µM for Hela cells; 500 nM for G361) for 6 hr, followed 701 
by treatment for a further 18 hr with vehicle (DMSO), or 100 or 250 µM etoposide. Results 702 
are numbers of colonies counted (mean ± SEM; n = 4) expressed as a percentage of 703 
survival in controls without etoposide. None of the effects of PBC were significant. (D) As 704 
(C), but using G361 cells; asterisks represent statistical significance of effects of PBC. (E) 705 
Effect of different concentrations of aphidicolin (Aph) on the cell cycle of HeLa cells, 706 
analyzed as in Figs. 7A and 7B. Asterisks indicate significant differences from the control 707 
without aphidicolin for each cell cycle phase. (F) Effect of 5 µM aphidicolin on clonogenic 708 
survival of HeLa cells treated with etoposide, analysed as in Figs 7C and 7D. Asterisks 709 
indicate significant differences from controls without etoposide. 710 
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